Acrivon Therapeutics, Inc. (ACRV)
$1.75-7.89%Close
SELLCRISIS · day 1
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $75M
- Beta
- 1.93
- P/E (TTM)
- -0.93
- Short % float
- 5.79%
- Days to cover
- 4.4
- SI change
- +34.4%
- 1W
- -5.91%
- 1M
- -10.71%
- vs SPY 1W
- -5.78%
- vs SPY 1M
- -13.22%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 12
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-42.1%
REV YoY-
ROE-70.1%
EPS YoY-
ROA-74.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.93
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.84
P/FCF-
EV/EBITDA-0.45
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E2.44
ALTMAN Z-
CURR RATIO7.99
ND/EBITDA-
BETA1.93
Company news
FAQ
- What is LOPJLB’s current signal on ACRV?
- LOPJLB’s latest quantitative signal on Acrivon Therapeutics, Inc. Common Stock (ACRV) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ACRV in?
- Acrivon Therapeutics, Inc. Common Stock (ACRV) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Acrivon Therapeutics, Inc. Common Stock (ACRV) do?
- Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Pro…